Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okamoto Shozo, Nomura Kaori, Shiga Tohru, Sugawara Shigeyasu, Oriuchi Noboru, Ito Hiroshi, Takahashi Kazuhiro, Joho Taiki, Kondo Yuto, Hanada Kazuhiko, Ishizuka Naoki, Kobayakawa Masao
Аннотация
PURPOSE: The efficacy of current therapeutic options for pheochromocytomas and paragangliomas, such as 131I-meta-iodobenzylguanidine (131I-MIBG), is limited owing to low complete response rates and a requirement for prolonged radiation isolation. In this regard, alpha-emitting meta-astatobenzylguanidine labeled with astatine-211 (²¹¹At-MABG) has demonstrated encouraging non-clinical results in mice, yet its clinical potential remains unclear. This first-in-human, open-label, single-arm, phase 1 clinical study aimed to evaluate the safety, pharmacokinetics, and recommended dose of 211At-MABG.
PATIENTS AND METHODS: Ten participants with unresectable or metastatic treatment-refractory pheochromocytomas or paragangliomas and confirmed 123I-MIBG uptake were enrolled between June 2022 and May 2025. Using a 3 + 3 dose-escalation design (0.65, 1.3, and 2.1 MBq/kg), they received a single intravenous dose of 211At-MABG.
RESULTS: No dose-limiting toxicities were observed during the 6-week evaluation period. The cumulative urinary excretion of 211At-MABG reached 65.0% within 72 h, indicating rapid systemic clearance. One, seven, and two patients exhibited a partial response, stable disease, and progressive disease, respectively, during a maximum follow-up period of 12 weeks.
CONCLUSIONS: A single dose of 211At-MABG at 2.1 MBq/kg was well tolerated and demonstrated predictable pharmacokinetics. Preliminary antitumor activity was observed, including one partial response during the 12-week period. These findings establish the clinical feasibility of ²¹¹At-MABG and provide a translational foundation for multi-dose, dose-escalation, and biomarker-stratified trials.
PATIENTS AND METHODS: Ten participants with unresectable or metastatic treatment-refractory pheochromocytomas or paragangliomas and confirmed 123I-MIBG uptake were enrolled between June 2022 and May 2025. Using a 3 + 3 dose-escalation design (0.65, 1.3, and 2.1 MBq/kg), they received a single intravenous dose of 211At-MABG.
RESULTS: No dose-limiting toxicities were observed during the 6-week evaluation period. The cumulative urinary excretion of 211At-MABG reached 65.0% within 72 h, indicating rapid systemic clearance. One, seven, and two patients exhibited a partial response, stable disease, and progressive disease, respectively, during a maximum follow-up period of 12 weeks.
CONCLUSIONS: A single dose of 211At-MABG at 2.1 MBq/kg was well tolerated and demonstrated predictable pharmacokinetics. Preliminary antitumor activity was observed, including one partial response during the 12-week period. These findings establish the clinical feasibility of ²¹¹At-MABG and provide a translational foundation for multi-dose, dose-escalation, and biomarker-stratified trials.